Artiva Biotherapeutics (ARTV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Good morning, everyone. Thank you for attending Jefferies Healthcare Conference. My name is Kelly Xu, one of the equity analysts here on the biotech team. We are very pleased to have Doctor. Fred Aslan, CEO of Ativa Biotherapeutics join us today. Welcome, Fred. Speaker1 Thank you, Kelly. Speaker0 And maybe let's first start with a big picture question. Many cell therapies in the autoimmune space originated from oncology and Ati ...

Relay Therapeutics (RLAY) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Okay. Well, let's get started. Hey everyone, thanks so much for attending the Jefferies Healthcare Conference. Really appreciate you guys being here so bright and early. I'm Amy Lee, I'm a biotech analyst and I have the pleasure of welcoming the Relay Therapeutics management team. We have Sanjeev Patel, the Chief Executive Officer Don Bergstrom, the President of R and D and Pete Raymer, the Chief Corporate Development Officer. So R ...

Assembly Biosciences (ASMB) 2025 Conference June 04, 2025 08:45 AM ET Speaker0 Good morning everyone. Welcome to the Jefferies Healthcare Conference. My name is Anthea Lee, part of the Healthcare Research Team here at Jefferies. We're very fortunate to have Assembly Biosciences with us today. We have Jason Okazaki, CEO, and CMO Anuj Ghajar. Welcome. For those that are new to the story, perhaps we just start with a quick overview of the company, the pipeline and key catalysts that you see coming up for the r ...

Sionna Therapeutics Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or other events to be materially different from any future results, performance or other events expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on forward-looking statements. Our actual future results, performance or other events may be materially different from what we expect. Exc ...

Tolimidone was originally discovered by Pfizer Inc. ("Pfizer") and was developed through Phase II for the treatment of gastric ulcers. Pfizer undertook a broad pre-clinical program to characterize the pharmacology, pharmacokinetics, metabolism and toxicology of tolimidone. Pfizer discontinued development of the drug due to lack of efficacy for that indication in a Phase 2 clinical trial. Tolimidone is a selective activator of the enzyme Lyn kinase which increases phosphorylation of insulin substrate -1, the ...

Core Insights - The BeautyHealth Company has reached a significant milestone with 35,000 Hydrafacial devices installed globally, solidifying its leadership in the hydradermabrasion market [1][2] - The Hydrafacial treatment has seen approximately 5 million treatments delivered in the past year, indicating strong demand and consumer trust [2][5] - Hydrafacial ranks as the second most recognized facial treatment in the U.S., with a 96% "Worth It" rating on RealSelf and a Net Promoter Score of 52, showcasing high consumer satisfaction [2][4] Company Performance - The Hydrafacial treatment is responsible for driving about 7% of new patients to medical spas and aesthetic practices annually, highlighting its role in practice growth [2][4] - The treatment combines seven skin therapies, resulting in visible improvements and a boost in consumer confidence with no downtime [2][3] Market Trends - There is a growing trend towards non-invasive aesthetic treatments that prioritize skin health, which aligns with the offerings of Hydrafacial [2][3] - The success of Hydrafacial reflects a shift in beauty trends favoring a natural and effortless look [2]

Core Viewpoint - Allarity Therapeutics has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance the understanding of the dual mechanism of action of its drug stenoparib, a novel cancer treatment [1][3]. Company Overview - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment [1][9]. - The company utilizes its proprietary Drug Response Predictor (DRP) technology to select patients who may benefit most from stenoparib [1][7]. Drug Mechanism and Collaboration - Stenoparib is an orally available small-molecule inhibitor that targets PARP1/2 and tankyrase1/2, impairing DNA repair and inhibiting the WNT signaling pathway, which is associated with chemoresistance in various cancers [2][6]. - The collaboration with IBRI will involve advanced studies to clarify how PARP inhibition and WNT pathway modulation contribute to stenoparib's anticancer effects [2][3]. Strategic Importance - Understanding stenoparib's dual biological effects is crucial for Allarity's long-term clinical development strategy, enhancing engagement with oncologists and biotech investors [3]. - The collaboration may also support future marketing approval efforts for stenoparib and clarify its mechanism of action in ongoing clinical trials for advanced ovarian cancer and recurrent small cell lung cancer [3][4]. Research Institute Profile - The Indiana Biosciences Research Institute (IBRI) is a leading translational research institute that focuses on solving high-impact biomedical challenges, including cancer [5].

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has entered into a consulting agreement with Leonard Wheeler, a former NFL player turned entrepreneur, author, corporate consultant, co-Executive Director of the NFL Legends Community, and more recently, na ...

Core Insights - BrainsWay has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to mental health care and raise awareness of innovative treatments [1][2] - The investment in Stella is part of a broader strategy to make minority-stake investments in high-performing mental health providers across the U.S. [2] - BrainsWay will invest $5 million in Stella, acquiring a minority position in the company through preferred, annually compounding securities [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay aims to increase global awareness and access to Deep TMS through ongoing clinical trials and scientific advancements [5] Stella Overview - Stella is an interventional psychiatry practice focused on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients across more than 20 clinics [1][6] - Stella's partnership with BrainsWay is expected to accelerate its growth and enhance patient care [3][5]

Core Insights - BrainsWay Ltd. has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to innovative mental health treatments [1][2] - The investment of $5 million will provide BrainsWay with a minority position in Stella, aimed at supporting the interventional psychiatry space [4][2] - This partnership is expected to accelerate growth and improve patient care through Stella's established network of mental health clinics [3][5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is focused on advancing neuroscience and increasing global awareness of its treatment options [5] Stella Overview - Stella is an interventional psychiatry practice that addresses severe trauma, stress, anxiety, and depression through a multidisciplinary approach [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients [1][6] - Stella aims to expand access to transformative mental health care through its network of clinics [3][5]